XTX Topco’s BridgeBio Pharma BBIO Stock Holding History

XTX Topco’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.69M	Buy	+116,611	New	+$8.17M	0.11%	162
2026 Q1	–	Sell	-13,169	Closed	-$1.01M	–	3841
2025 Q4	$1.01M	Buy	13,169 +8,150	+162%	+$535K	0.03%	1019
2025 Q3	$261K	Buy	+5,019	New	+$245K	0.01%	1619
2025 Q2	–	Sell	-34,601	Closed	-$1.2M	–	2369
2025 Q1	$1.2M	Buy	34,601 +21,272	+160%	+$717K	0.06%	454
2024 Q4	$366K	Buy	+13,329	New	+$344K	0.03%	1042
2024 Q3	–	Sell	-12,096	Closed	-$306K	–	2089
2024 Q2	$306K	Sell	12,096 -4,460	-27%	-$122K	0.03%	949
2024 Q1	$512K	Buy	16,556 +10,278	+164%	+$350K	0.07%	475
2023 Q4	$253K	Buy	+6,278	New	+$189K	0.06%	767
2023 Q3	–	Sell	-20,248	Closed	-$348K	–	1566
2023 Q2	$348K	Buy	+20,248	New	+$305K	0.06%	611
2023 Q1	–	Sell	-36,952	Closed	-$282K	–	1273
2022 Q4	$282K	Sell	36,952 -30,518	-45%	-$292K	0.06%	620
2022 Q3	$671K	Buy	+67,470	New	+$701K	0.17%	133
2022 Q2	–	Sell	-15,051	Closed	-$153K	–	850
2022 Q1	$153K	Buy	+15,051	New	+$154K	0.07%	456
2021 Q4	–	Sell	-7,174	Closed	-$336K	–	686
2021 Q3	$336K	Buy	+7,174	New	+$385K	0.11%	308

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

XTX Topco's BBIO Position: Q2 2026 in Review

XTX Topco opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 116,611 shares worth $8.69M. The stake represents 0.11% of the portfolio and ranks #162 among its holdings. This is a return to the name: XTX Topco previously reported a position in BBIO as recently as Q4 2025.

XTX Topco first reported a position in BBIO in Q3 2021 and has held it in 13 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

XTX Topco held 116,611 shares of BridgeBio Pharma worth $8.69M as of Q2 2026.
BridgeBio Pharma was a new XTX Topco position in Q2 2026.
BridgeBio Pharma made up 0.11% of XTX Topco's portfolio in Q2 2026, its #162 holding.
XTX Topco first reported a position in BridgeBio Pharma in Q3 2021 and has held it in 13 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.